SUPRIYA.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 11:59):

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide...

Stats
Tagesvolumen	400 364
Durchschnittsvolumen	596 440
Marktkapitalisierung	32.96B
EPS	INR2.97 ( 2023-11-07 )
Last Dividend	INR0.600 ( 2023-09-15 )
Next Dividend	INR0 ( N/A )
P/E	27.39
ATR14	INR0.808 (0.20%)

Volumen Korrelation

Lang: -0.73 (moderate negative)

Kurz: -0.84 (strong negative)

Signal:(46.383) Neutral

Supriya Lifescience Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Supriya Lifescience Korrelation - Währung/Rohstoff

-0.21
( neutral )

0.01
( neutral )

0.38
( neutral )

-0.33
( neutral )

-0.17
( neutral )

-0.31
( neutral )

Supriya Lifescience Finanzdaten

Annual	2022
Umsatz:	INR4.61B
Bruttogewinn:	INR2.80B (60.77 %)
EPS:	INR11.16

FY	2022
Umsatz:	INR4.61B
Bruttogewinn:	INR2.80B (60.77 %)
EPS:	INR11.16

FY	2022
Umsatz:	INR5.19B
Bruttogewinn:	INR2.89B (55.74 %)
EPS:	INR18.86

FY	2021
Umsatz:	INR3.85B
Bruttogewinn:	INR2.34B (60.77 %)
EPS:	INR48.47

Financial Reports:

No articles found.

Supriya Lifescience Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0.600 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0.600 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Supriya Lifescience Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.03 - low (34.06%) | Divividend Growth Potential Score: 3.57 - Decrease likely (28.63%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.600	2022-09-01
Last Dividend	INR0.600	2023-09-15
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	INR1.200	--
Avg. Dividend % Per Year	0.10%	--
Score	1.7	--
Div. Sustainability Score	4.03
Div.Growth Potential Score	3.57
Div. Directional Score	3.80	--

Next Divdend (Est)
(2024-07-01)

INR0.400 Estimate 3.00 %

Dividend Stability

0.24 Very Poor

Dividend Score

1.70

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2022	INR0.600	0.12%
2023	INR0.600	0.25%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SMLT.NS	Dividend Knight	2023-08-09	Semi-Annually	3	0.64%
MIDHANI.NS	Dividend Junior	2023-09-22	Semi-Annually	7	1.04%
HAVELLS.NS	Dividend Junior	2023-06-02	Annually	23	0.43%
BECTORFOOD.NS	Dividend Junior	2023-09-22	Semi-Annually	4	0.39%
PUNJABCHEM.NS	Dividend Junior	2023-07-27	Sporadic	18	0.16%
KENNAMET.NS	Dividend Knight	2023-05-25	Annually	4	0.76%
ELECTCAST.NS	Dividend Junior	2023-09-04	Annually	23	1.51%
AHLUCONT.NS	Dividend Junior	2023-09-22	Sporadic	15	0.04%
SUNPHARMA.NS	Dividend Junior	2023-07-28	Semi-Annually	29	0.77%
NAVA.NS	Dividend Knight	2023-07-24	Annually	23	2.35%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.217	1.500	5.66	8.48	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.166	1.500	9.27	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	66.65	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	3.70	2.00	8.77	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.70	2.00	8.15	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.619	1.000	3.01	3.01	[0.2 - 0.8]
operatingProfitMarginTTM	0.298	1.000	6.04	6.04	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.03

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	27.37	1.000	7.34	0	[1 - 100]
returnOnEquityTTM	0.166	2.50	9.53	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.70	2.00	8.77	10.00	[0 - 30]
dividendYielPercentageTTM	0.147	1.500	6.34	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.70	2.00	8.77	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.670	1.500	-7.80	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0538	1.000	-1.156	0	[0.1 - 0.5]
Total Score				3.57

Supriya Lifescience

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.